Risk of All-Cause Mortality in US Adults With Preserved Ratio Impaired Spirometry: An Observational Study.

IF 2.7 3区 医学 Q2 RESPIRATORY SYSTEM
Shan Xiao, Jie Ou, Wangli Qiu, Chunxin Ye, Na Li, Sida Chen, Yuting Lai, Zhishan Deng, Fan Wu, Yan Shen
{"title":"Risk of All-Cause Mortality in US Adults With Preserved Ratio Impaired Spirometry: An Observational Study.","authors":"Shan Xiao, Jie Ou, Wangli Qiu, Chunxin Ye, Na Li, Sida Chen, Yuting Lai, Zhishan Deng, Fan Wu, Yan Shen","doi":"10.2147/COPD.S497674","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Preserved ratio impaired spirometry (PRISm) is defined as forced expiratory volume in one second (FEV<sub>1</sub>)/forced vital capacity (FVC)≥0.70 and FEV<sub>1</sub><80% predicted. Previous studies have shown that individuals with PRISm may develop airflow obstruction and have an increased mortality risk. However, studies with long-term follow-up are lacking, and this topic has not been evaluated in the general population. We explored the all-cause mortality risk of individuals with PRISm in a large sample of the general population.</p><p><strong>Methods: </strong>We used data from the National Health and Nutrition Examination Survey III and 2007-2012. Participants aged 20-79 years at baseline and who underwent spirometry were included. Normal spirometry was defined as a prebronchodilator FEV<sub>1</sub>/FVC≥0.70 and FEV<sub>1</sub>≥80% predicted. We used Cox proportional hazards regression models to compare all-cause mortality between the groups. We performed sensitivity analyses stratified by the lower limit of normal definition of spirometry criteria. Subgroup analyses by sex, age, smoking status, race, body mass index, level of education, poverty-to-income ratio, respiratory symptoms, and comorbidities were performed in participants with the different spirometry classifications.</p><p><strong>Results: </strong>Overall, 24,691 participants were included, with a median follow-up time of 25.7 years. Of these, 19,969 had normal spirometry and 1,452 had PRISm. PRISm was associated with a high all-cause mortality risk (unadjusted hazard ratio [HR]=2.47, 95% confidence interval [CI]: 2.25-2.71, P<0.001; adjusted HR=1.69, 95% CI: 1.54-1.86, P<0.001) compared with normal spirometry. Sensitivity analyses and subgroup analyses showed a similar increased all-cause mortality risk in PRISm.</p><p><strong>Conclusion: </strong>Our finding revealed that PRISm was significantly associated with increased risk of all-cause mortality in the general population compared with normal spirometry. Further research is needed to explore the intervention effect of PRISm.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"287-302"},"PeriodicalIF":2.7000,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829583/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Chronic Obstructive Pulmonary Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/COPD.S497674","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Preserved ratio impaired spirometry (PRISm) is defined as forced expiratory volume in one second (FEV1)/forced vital capacity (FVC)≥0.70 and FEV1<80% predicted. Previous studies have shown that individuals with PRISm may develop airflow obstruction and have an increased mortality risk. However, studies with long-term follow-up are lacking, and this topic has not been evaluated in the general population. We explored the all-cause mortality risk of individuals with PRISm in a large sample of the general population.

Methods: We used data from the National Health and Nutrition Examination Survey III and 2007-2012. Participants aged 20-79 years at baseline and who underwent spirometry were included. Normal spirometry was defined as a prebronchodilator FEV1/FVC≥0.70 and FEV1≥80% predicted. We used Cox proportional hazards regression models to compare all-cause mortality between the groups. We performed sensitivity analyses stratified by the lower limit of normal definition of spirometry criteria. Subgroup analyses by sex, age, smoking status, race, body mass index, level of education, poverty-to-income ratio, respiratory symptoms, and comorbidities were performed in participants with the different spirometry classifications.

Results: Overall, 24,691 participants were included, with a median follow-up time of 25.7 years. Of these, 19,969 had normal spirometry and 1,452 had PRISm. PRISm was associated with a high all-cause mortality risk (unadjusted hazard ratio [HR]=2.47, 95% confidence interval [CI]: 2.25-2.71, P<0.001; adjusted HR=1.69, 95% CI: 1.54-1.86, P<0.001) compared with normal spirometry. Sensitivity analyses and subgroup analyses showed a similar increased all-cause mortality risk in PRISm.

Conclusion: Our finding revealed that PRISm was significantly associated with increased risk of all-cause mortality in the general population compared with normal spirometry. Further research is needed to explore the intervention effect of PRISm.

背景:一秒钟用力呼气容积(FEV1)/用力肺活量(FVC)≥0.70 和 FEV1Methods.保留比率受损肺活量(PRISm)被定义为一秒钟用力呼气容积(FEV1)/用力肺活量(FVC)≥0.70:我们使用了美国国家健康与营养调查 III 和 2007-2012 年的数据。基线年龄在 20-79 岁之间、接受过肺活量测定的参与者均被纳入其中。正常肺活量的定义是支气管扩张前 FEV1/FVC≥0.70 和 FEV1≥80% 预测值。我们使用 Cox 比例危险回归模型来比较不同组间的全因死亡率。我们根据肺活量标准的正常定义下限进行了分层敏感性分析。我们对不同肺活量分类的参与者按性别、年龄、吸烟状况、种族、体重指数、教育水平、贫困与收入比、呼吸系统症状和合并症进行了分组分析:共纳入 24,691 名参与者,中位随访时间为 25.7 年。其中 19969 人肺活量正常,1452 人患有 PRISm。PRISm与较高的全因死亡风险相关(未经调整的危险比[HR]=2.47,95%置信区间[CI]:2.25-2.71,PC结论:我们的研究结果表明,与正常肺活量相比,PRISm 与普通人群全因死亡风险的增加显著相关。还需要进一步研究来探讨 PRISm 的干预效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.80
自引率
10.70%
发文量
372
审稿时长
16 weeks
期刊介绍: An international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus will be given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols. This journal is directed at specialists and healthcare professionals
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信